stockrow
Friday 6 November 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- +35.3%
- Free cash flow
- +12.8%
- Total debt
- +0.05%
Quarter to September 2026, against a year earlier
11.23
8.61
−43.40%
Follow BDSX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.58 | 1.46 | 2.26 | 3.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
66.00 | (13.77) | (148.64) | (44.15) | |
P/B ratio |
0.00 | 15.33 | 25.39 | 36.66 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.90 | 1.67 | 2.42 | 3.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.43) | (6.48) | (12.56) | (18.55) | |
EV/FCF |
(3.37) | (6.37) | (12.21) | (17.49) | |
Quick Ratio |
1.61 | 2.42 | 2.56 | 2.63 | |
Current Ratio |
1.87 | 2.82 | 2.85 | 2.96 | |
Net Debt/EBITDA |
(125.39) | (4.70) | (4.63) | 0.00 | |
Debt/Assets |
54.24% | 49.12% | 49.11% | 50.19% | |
Debt/Equity |
(19.25) | 5.09 | 5.12 | 5.43 | |
Asset Turnover |
0.96 | 1.06 | 1.12 | 1.15 | |
Operating CF/Net income |
(0.20) | 1.30 | 0.21 | 0.90 | |
Capex/Depreciation |
(0.06) | (0.08) | (0.14) | 0.00 | |
Interest Coverage |
(0.96) | (3.14) | (2.72) | — | |
Research and Development Expense of Revenue |
9.98% | 12.85% | 11.67% | 12.45% | |
Selling, General and Administrative Expense of Revenue |
79.89% | 94.94% | 90.40% | 93.59% | |
Intangible Assets out of Total Assets |
0.22 | 0.20 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
3.74% | 4.36% | 3.05% | 3.54% | |
Graham Net Nets |
(1.12) | (0.32) | (0.18) | (0.14) | |
Graham Number |
5.97 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(71.32%) | (28.00%) | (14.06%) | (9.25%) | |
Free Cash Flow Yield |
(46.11%) | (18.03%) | (8.79%) | (6.06%) | |
Revenue per Share |
3.81 | 2.65 | 2.61 | 2.26 | |
Operating CF per Share |
0.10 | (1.05) | (0.15) | (0.68) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.06) | |
Free Cash Flow per Share |
0.09 | (1.07) | (0.18) | (0.73) | |
Cash per Share |
2.51 | 2.65 | 2.91 | 2.67 | |
Shareholders Equity per Share |
(0.33) | 0.95 | 0.89 | 0.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.33) | 0.95 | 0.89 | 0.81 | |
Free Cash Flow |
0.67 | (10.31) | (1.82) | (7.80) | |
Working Capital |
15.08 | 26.42 | 28.27 | 27.89 | |
Capital Expenditures |
(0.10) | (0.14) | (0.25) | (0.60) | |
Net Current Asset Value |
(57.42) | (44.59) | (42.62) | (43.13) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.82 | 8.57 | 8.28 | 10.90 | |
Average Payables |
2.64 | 3.29 | 2.57 | 3.12 | |
Average Assets |
92.36 | 90.44 | 91.53 | 91.33 | |
Average Common Equity |
9.21 | 10.10 | 5.14 | 3.48 |
Columns are period end dates · fundamentals updated 5 Nov 2026